| Ulcerative Colitis

Humira vs Zeposia

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.

Deep comparison between: Humira vs Zeposia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZeposia has a higher rate of injection site reactions vs Humira based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zeposia but not Humira, including UnitedHealthcare

Category

Humira

Zeposia

At A Glance

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha antagonist

RouteOral

FrequencyOnce daily

ClassS1P receptor modulator

Indications

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Chronic small plaque psoriasis
Hidradenitis Suppurativa
Uveitis

Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Secondary Progressive
Clinically isolated syndrome
Ulcerative Colitis

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.

Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.

Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.

Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).

Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.

Contraindications

—

Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
Severe untreated sleep apnea
Concurrent use of a monoamine oxidase (MAO) inhibitor

Drug Interactions

1222View drug interactions

1035View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.

Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)

Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome

Postmarketing Liver injury

Pharmacology

Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.

Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Humira